Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy

Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) are among the most frequent indications for allogeneic hematopoietic cell transplantation (allo-HCT). Allo-HCT represents the sole option with curative potential for many patients and is standard of care for fit patients with high-risk disease features. Survival at 3 years after allo-HCT is between 50% and 60% for patients with AML in remission, approximately 30% for patients with relapsed/refractory AML, and between 45% and 55% for patients with MDS [1].

Source: Biology of Blood and Marrow Transplantation - May 22, 2021 Category: Hematology Authors: Corrado Zuanelli Brambilla, Stephanie M. Lobaugh, Josel D. Ruiz, Parastoo B. Dahi, Aaron D. Goldberg, James W. Young, Boglarka Gyurkocza, Brian C. Shaffer, Doris M. Ponce, Roni Tamari, Miriam Sanchez Escamilla, Nerea Castillo Flores, Ioannis Politikos, Mi Source Type: research